Literature DB >> 25219973

YKL-40 in cerebrospinal fluid in Huntington's disease--a role in pathology or a nonspecific response to inflammation?

Tua Vinther-Jensen1, Esben Budtz-Jørgensen2, Anja H Simonsen3, Jørgen E Nielsen1, Lena E Hjermind4.   

Abstract

Entities:  

Keywords:  Huntington's disease; Neuroinflammation; YKL-40

Mesh：

Substances：

Year:  2014        PMID： 25219973     DOI： 10.1016/j.parkreldis.2014.08.011

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN： 1353-8020            Impact factor:   4.891


× No keyword cloud information.
  10 in total

Review 1.  Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.

Authors:  Sarah J Tabrizi; Carlos Estevez-Fraga; Willeke M C van Roon-Mom; Michael D Flower; Rachael I Scahill; Edward J Wild; Ignacio Muñoz-Sanjuan; Cristina Sampaio; Anne E Rosser; Blair R Leavitt
Journal:  Lancet Neurol       Date:  2022-07       Impact factor: 59.935

2.  Platelet-derived extracellular vesicles in Huntington's disease.

Authors:  Hélèna L Denis; Jérôme Lamontagne-Proulx; Isabelle St-Amour; Sarah L Mason; Andreas Weiss; Sylvain Chouinard; Roger A Barker; Eric Boilard; Francesca Cicchetti
Journal:  J Neurol       Date:  2018-09-12       Impact factor: 4.849

3.  Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease.

Authors:  Tua Vinther-Jensen; Lars Börnsen; Esben Budtz-Jørgensen; Cecilie Ammitzbøll; Ida U Larsen; Lena E Hjermind; Finn Sellebjerg; Jørgen E Nielsen
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-09-28

Review 4.  YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer's Disease.

Authors:  Paweł Muszyński; Magdalena Groblewska; Agnieszka Kulczyńska-Przybik; Alina Kułakowska; Barbara Mroczko
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

5.  Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders.

Authors:  Everard G B Vijverberg; Annemiek Dols; Welmoed A Krudop; Marta Del Campo Milan; Cora J Kerssens; Flora Gossink; Niels D Prins; Max L Stek; Philip Scheltens; Charlotte E Teunissen; Yolande A L Pijnenburg
Journal:  Alzheimers Dement (Amst)       Date:  2017-03-02

Review 6.  Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies.

Authors:  Natalia P Rocha; Fabiola M Ribeiro; Erin Furr-Stimming; Antonio L Teixeira
Journal:  Mediators Inflamm       Date:  2016-08-08       Impact factor: 4.711

7.  Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease.

Authors:  Filipe Brogueira Rodrigues; Lauren M Byrne; Peter McColgan; Nicola Robertson; Sarah J Tabrizi; Henrik Zetterberg; Edward J Wild
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

8.  Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease.

Authors:  Valter Niemelä; Joachim Burman; Kaj Blennow; Henrik Zetterberg; Anders Larsson; Jimmy Sundblom
Journal:  PLoS One       Date:  2018-02-23       Impact factor: 3.240

Review 9.  Expanding the Arsenal Against Huntington's Disease-Herbal Drugs and Their Nanoformulations.

Authors:  Sukriti Vishwas; Monica Gulati; Bhupinder Kapoor; Saurabh Gupta; Sachin Kumar Singh; Ankit Awasthi; Arzoo Khan; Aditya Goyal; Anil Bansal; Suman Baishnab; Thakur Gurjeet Singh; Sandeep Arora; Omji Porwal; Ankit Kumar; Vijay Kumar
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

Review 10.  Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.

Authors:  Sarah J Tabrizi; Michael D Flower; Christopher A Ross; Edward J Wild
Journal:  Nat Rev Neurol       Date:  2020-08-14       Impact factor: 42.937
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.